Savient Pharmaceuticals, Inc. (NASDAQ:SVNT)
A biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
double down on SVNT based on future sales predictions of the one gout drug.
Recs
Market Maker Selling phase soon?
Recs
This is not a safe investment. However, the long term growth potential from its revolutionary new drug (Krystexxa) just cannot be overlooked. At an annual price of $59,000, if Krystexxa captures even a fraction of the estimated 5 million to 8 million U.S. gout patients, it could drive significant revenue for Savient.
Recs
There are currently 115000 SVNT shares in my "fund" with break-even of around 3.34 USD.
http://caps.fool.com/Blogs/fund-trades/671856.
Recs
jcode
Recs
Technical Monthly
Recs
This one has better potential of going up and less risk of going down in long term from this point on. Co will be bought out at a price more than what it is trading at now.
Recs
The market has oversold biotech shares and this company was also affected. I beat it will growth >100%
Recs
4 Fallen Bevo picks that are based in US that have very high short interest and are currently above $1/share.
FRZ, SVNT, JRCC, PCBC
Recs
New FDA approved drug sales starting this year.
Recs
Euro247 haiku
Did not sell oh well
Plenty money of their own
Drug demand will grow!
Recs
short squeeze ahoy
Recs
Recs
Recs
Extremely High Price for Book Value
Recs
When Savient get their sales team together and prove that the gout drug is a winner, they should become a play once again for the major pharmas.
Recs
I like TSIF's pitch.
Recs
SVNT will market it's new gout medicine in Dec. It needs money soon (bummer) but can probably get it (cool) though that MIGHT dampen price (possible bummer). The bad news is all in the price (cool) and it MIGHT find a buyer after all (cool) or successfully market its much praised in advance med (cool). On balance, the chart and "story" look sideways followed by up. #
Recs
Slammed almost 50% because it couldn't find a buyer at it's already run-up speculated price. Remember it still has a fresh FDA approval of Krystexxa for arthritis, so the risk/reward at this point is very appealing.
Potential for a quick pop from another (albeit lower) buyout price, or it can ride the Krystexxa sales for a while.
Recs
The stock completely overacted
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 70 : 1 2 3 4 Next »